Caicun Zhou - Publications, H-index & Citations

Caicun Zhou

Shanghai East Hospital

49H指数

389论文数

1.1W被引数

收录论文 93

发表时间

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study 甲磺酸厄洛替尼与吉非替尼作为EGFR突变非小细胞肺癌的一线治疗：一项随机、双盲、多中心III期研究

Signal Transduction and Targeted Therapy

IF52.7

2026-08-13

OAAI

Jia Yu; Anwen Xiong; Qiming Wang; Jianhua Chen; Hongrui Niu; Chengzhi Zhou; Panwen Tian; Wu Zhuang; Jie Li; Jing Wang; Junguo Lu; Kangsheng Gu; Jinsheng Shi; Jun Guo; Yonghui Di; Dongqing Lv; Debin Sun; Liming Cao; Zhixiong Yang; Jingxun Wu; Liyun Miao; Yueyin Pan; Chong Li; Xiaohong Wu; Jie Yin; Xiang Wang; Meili Sun; Miao He; Shundong Cang; Haohui Fang; Ping Chen; Min Zhang; Xinmei Yang; Hui Zhao; Jian Feng; Xuezhen Ma; Sheng Hu; Jian Lu; Xin Zhao; Zhixiang Zhuang; Yilan Sun; Xu Sun; Bing Yu; Chaonan Zhu; Jianghua Chen; June Xu; Kai Wang; Caicun Zhou

Clinical utility of molecular residual disease detection in early-stage resected EGFR-mutated non-small cell lung cancer EGFR突变型早期可切除非小细胞肺癌中分子残留病灶检测的临床应用

Nature Communications

IF15.7

2026-08-10

OAAI

Fei Zhou; Chunxia Su; Wenhua Liang; Li-Di Xu; Wei Tao; Juanjuan Qian; Shidong Xu; Dan Liu; Rui Fan; Yaxi Zhang; Yiqian Liu; Lin Wu; Xiangning Fu; Xiaodong Zhang; Ning Shen; Di Ge; Qun Chen; Weimin Mao; Lin Xu; Chun Chen; Bing Hu; Guoguang Shao; Jian Hu; Jian Zhao; Xiaoqing Liu; Zhidong Liu; Zheng Wang; Zemin Xiao; Taiqian Gong; Wen Lin; Xingya Li; Feng Ye; Yang Liu; Haitao Ma; Yunchao Huang; Jianying Zhou; Zhonglin Wang; Junke Fu; Lieming Ding; Li Mao; Weizhi Chen; Jianxing He; Caicun Zhou

Phase 1b Multicenter Study of SG001; a Humanized Anti-PD-1 Antibody; in Patients with Advanced Solid Tumors I期b多中心研究SG001；一种人源化抗PD-1抗体；在晚期实体瘤患者中的应用

Drug Design; Development and Therapy

IF0

2025-11-24

OAAI

Jian Fang; Ou Jiang; Wei Li; Jie Lin; Meiyu Fang; Qun Li; Weihong Zhao; Ke Wang; Huaqiu Shi; Zhendong Chen; Junyan Yu; Xiaojing Xing; Mingxuan Zhao; Anwen Liu; Wei Wang; Zhengquan Han; Silong Xiang; Xiao Zhang; Jin Li; Caicun Zhou

Bevacizumab plus chemotherapy versus chemotherapy in untreated advanced non-squamous non-small-cell lung cancer patients with brain metastases (BAP BRAIN): an open-label, randomized, multicenter, phase III study 贝伐珠单抗联合化疗与化疗对比治疗未经治疗的伴有脑转移的晚期非鳞非小细胞肺癌患者（BAP BRAIN）：一项开放标签、随机、多中心、III期研究

ESMO Open

IF8.3

2025-11-20

OAAI

M. Li; Y. Pan; G. Jiang; Q. Wang; G. Wu; W. Feng; C. Zhou; Q. Bu; S. Ma; H. Jiang; J. Chen; H. Yu; M. Yu; Q. Liu; X. Hou; L. Chen

Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study Amivantamab-化疗在EGFR外显子20插入的非小细胞肺癌中的应用：来自III期PAPILLON研究的治疗交叉和其他终点的影响

Targeted Oncology

IF4

2025-11-03

OAAI

Rachel E. Sanborn; Caicun Zhou; Ke-Jing Tang; Byoung Chul Cho; Susanna Cheng; Sanjay Popat; Akira Ono; Shun Lu; Margarita Majem; Andres Aguilar; Maria Del Rosario Garcia Campelo; Hidetoshi Hayashi; Kang-yun Lee; Se-Hoon Lee; Angelo Delmonte; Jorge Alatorre-Alexander; Gary Richardson; Victor Santos; Christophe Dooms; Joshua K. Sabari; Catherine A. Shu; Nicolas Girard; Aaron S. Mansfield; Keunchil Park; Yichuan Xia; Archan Bhattacharya; Nasuh Buyukkaramikli; Nolen Perualila; Joris Diels; Sandip Acharya; Conor Chandler; Irina Proskorovsky; Lindsay Dearden; Honeylet Wortman-Vayn; Parthiv J. Mahadevia; Roland E. Knoblauch; Trishala Agrawal; Mahadi Baig; Enriqueta Felip

Cost-effectiveness of PD-L1 testing to guide immunotherapy for patients with advanced non-small-cell lung cancer in China PD-L1检测在中国指导晚期非小细胞肺癌患者免疫治疗的经济性研究

Journal of Comparative Effectiveness Research

IF2.5

2025-11-01

PREAI

Zhou, Fei; Li, Yuan; Ming, Jian; Chen, Yingyao; Zhou, Caicun

EP.18.06 ML44840: A Multicenter Prospective Cohort Study of the Patient-Reported Outcomes in Chinese Patients With ALK+ Advanced NSCLC EP.18.06 ML44840：一项关于ALK+晚期NSCLC中国患者报告结局的多中心前瞻性队列研究

Journal of Thoracic Oncology

IF20.8

2025-10-23

PREAI

C. Zhou; F. Zhou; Z. Song; H. Wang

GSTA1 conferred tolerance to osimertinib and provided strategies to overcome drug-tolerant persister in EGFR-mutant lung adenocarcinoma GSTA1赋予了对osimertinib的耐受性，并为克服EGFR突变型肺腺癌中药物耐受性持续存在提供了策略。

Journal of Thoracic Oncology

IF20.8

2025-10-10

PREAI

Xiaoshen Zhang; Yaokai Wen; Fengying Wu; Yu Jiang; Yuechun Lin; Lei Wang; Fei Zhou; Yue Shen; Zhen Min; Wei Li; Wenhua Liang; Jianxing He; Caicun Zhou

Long-term safety analysis of pooled data for tislelizumab as monotherapy or in combination with chemotherapy in patients with advanced cancers 替雷利珠单抗作为单药治疗或与化疗联合治疗晚期癌症患者的合并数据长期安全性分析

ONCOLOGIST

IF4.2

2025-07-01

OAAI

Zhou, Caicun; Huang, Rose; Yuan, Yuan; Schnell, Patrick; Wu, John; Kadva, Alysha; Mehmeti, Jola; Ajani, Jaffer

Development and application of a whole transcriptome sequencing assay for the detection of gene fusions in clinical cancer specimens 发展和应用一种全转录组测序检测方法，用于临床肿瘤标本中基因融合的检测

BMC CANCER

IF3.4

2025-05-08

OAAI

Zhao, Songchen; Du, Xinhua; Zhang, Yan; Bai, Jing; Meng, Lu; Li, Xuefei; Ma, Jiaxin; Sheng, HeYu; Fu, Xiaorui; Guan, Yanfang; Yi, Yuting; Yang, Ling; Xia, Xuefeng; Yi, Xin; Tan, Xinxin; Zhou, Caicun

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer 泛亚适应ESMO临床实践指南，用于癌基因成瘾的转移性非小细胞肺癌患者的诊断，治疗和随访

ESMO OPEN

IF8.3

2024-12-01

PREAI

Lee, S. -h.; Menis, J.; Kim, T. M.; Kim, H. R.; Zhou, C.; Kurniawati, S. A.; Prabhash, K.; Hayashi, H.; Lee, D. d. -w.; Imasa, M. S.; Teh, Y. L.; Yang, J. c. -h.; Reungwetwattana, T.; Sriuranpong, V.; Wu, C. -e.; Ang, Y.; Sabando, M.; Thiagarajan, M.; Mizugaki, H.; Noronha, V.; Yulianti, M.; Zhang, L.; Smyth, E.; Yoshino, T.; Park, J. O.; Pentheroudakis, G.; Park, S.; Peters, S.; Ahn, J. B.; Popat, S.

Cross-over adjusted overall survival for amivantamab plus chemotherapy vs chemotherapy in first-line EGFR exon-20 insertion NSCLC 与化疗相比，阿曼曲妥珠单抗联合化疗在一线EGFR外显子20插入性非小细胞肺癌中的交叉校正总生存期

ANNALS OF ONCOLOGY

IF65.4

2024-12-01

PREAI

Lu, S.; Zhou, C.; Cho, B. C.; Ono, A.; Hayashi, H.; Majem, M.; Lee, S-H.; Richardson, G.; Sabari, J. K.; Girard, N.; Sanborn, R. E.; Mansfield, A. S.; Buyukkaramikli, N.; Perualila, N.; Acharya, S.; Chandler, C.; Dearden, L.; Agrawal, T.; Baig, M.; Park, K.

A multicenter cluster randomized controlled study to evaluate guideline adoption through lung cancer clinical care quality improvement project (QIP) in pulmonary and critical care medicine (PCCM) department in China 一项多中心整群随机对照研究，旨在通过中国PCCM（肺与重症医学科）部门的肺癌临床护理质量改进项目（QIP）评估指南采纳情况。

ANNALS OF ONCOLOGY

IF65.4

2024-12-01

PREAI

Li, W.; Ren, Y.; Hu, C.; Song, Y.; Yang, S.; Zhou, C.; Zhang, X.; Zhang, Y.; Cao, B.; Wang, C.

The changing treatment landscape of EGFR-mutant non-small-cell lung cancer EGFR突变型非小细胞肺癌治疗前景的变化

NATURE REVIEWS CLINICAL ONCOLOGY

IF82.2

2024-11-29

PREAI

Zhou, Fei; Guo, Haoyue; Xia, Yang; Le, Xiuning; Tan, Daniel S. W.; Ramalingam, Suresh S.; Zhou, Caicun

IMpower010: Characterisation of patients (pts) with stage II-IIIA PD-L1 TC≥50% NSCLC who were disease-free at 5 years (5yDF) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after resection and adjuvant (adj) chemotherapy (chemo)IMpower010：评估在阿替利珠单抗（atezo）对比最佳支持治疗（BSC）的III期研究中，接受手术切除和辅助化疗（chemo）后，处于II-IIIA期PD-L1肿瘤细胞阳性率（TC）≥50%的非小细胞肺癌（NSCLC）患者中，5年无病生存（5yDF）患者的特征。

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Felip, E.; Vallieres, E.; Gologordko, O.; Martinez-Marti, A.; Zhou, C.; Altorki, N. K.; Rittmeyer, A.; Chella, A.; Reck, M.; Schuette, W.; Okada, M.; Liersch, R.; Teixeira, M. E.; Bennett, E.; Gitlitz, B. J.; Srivastava, M.; Ballinger, M.; Zhu, C.; Crama, L.; Wakelee, H.

Genomic correlates of the response to first-line PD-1 blockade plus chemotherapy in patients with advanced non-small-cell lung cancer 晚期非小细胞肺癌患者对一线PD-1阻断加化疗反应的基因组相关性

CHINESE MEDICAL JOURNAL

IF7.3

2024-08-21

OAAI

Jiang, Tao; Chen, Jian; Wang, Haowei; Wu, Fengying; Chen, Xiaoxia; Su, Chunxia; Zhang, Haiping; Zhou, Fei; Yang, Ying; Zhang, Jiao; Sun, Huaibo; Zhang, Henghui; Zhou, Caicun; Ren, Shengxiang

Plain language summary of PAPILLON: amivantamab plus chemotherapy in untreated EGFR-mutated non-small-cell lung cancer

FUTURE ONCOLOGY

IF2.6

2024-07-16

OAAI

Sabari, Joshua K.; Girard, Nicolas; Mansfield, Aaron S.; Sanborn, Rachel E.; Agrawal, Trishala; Zhou, Caicun; Park, Keunchil

NTRK gene fusion testing and management in lung cancer 肺癌NTRK基因融合检测与管理

CANCER TREATMENT REVIEWS

IF10.5

2024-06-01

OAAI

Repetto, Matteo; Garassino, Marina Chiara; Loong, Herbert H.; Lopez-Rios, Fernando; Mok, Tony; Peters, Solange; Planchard, David; Popat, Sanjay; Rudzinski, Erin R.; Drilon, Alexander; Zhou, Caicun

BGB-LC-201 (NCT05635708): A phase 2, open-label, multi-arm study of tislelizumab (TIS; anti-PD-1) in combination with investigational agents plus /- chemotherapy as first-line treatment for patients with locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC)

CANCER RESEARCH

IF16.6

2024-04-05

PREAI

Blumenschein, George; Besse, Benjamin; Gainor, Justin F.; Huang, DingZhi; Kao, Steven; Lee, Se-Hoon; Paz-Ares, Luis; Chen, Xin; He, Wanyu; Gururangan, Sridharan; Zhang, Kathy; Zhou, Caicun

IMpower010: Updated overall survival and safety results from Asian patients in a Phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA NSCLC

CANCER RESEARCH

IF16.6

2024-04-05

PREAI

Wang, Jie; Fan, Yun; Fang, Jian; He, Jianxing; Liu, Yunpeng; Tao, Min; Altorki, Nasser; Felip, Enriqueta; Wakelee, Heather; Vallieres, Eric; Belleli, Rossella; McNally, Virginia; Bennett, Elizabeth; Gitlitz, Barbara J.; Zhou, Caicun

研究方向